(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
08 January 2026 (08.01.2026)

WIPO | PCT

(10) International Publication Number
WO 2026/010658 A2

(51) International Patent Classification:
Not classified

(21) International Application Number:
PCT/US2025/021148

(22) International Filing Date:
24 March 2025 (24.03.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/568,863 22 March 2024 (22.03.2024) US

(71) Applicants: **NUCLIDIUM AG** [CH/CH]; Im Erasmushaus, Baumleingasse 18, 4051 Basel (CH). **UNIVERSITY OF BASEL** [CH/CH]; Vizerektorat Forschung, Petersgraben 35, 4001 Basel (CH).


(72) Inventors: **JAAFAR-THIEL, Leila**; Im Erasmushaus, Baumleingasse 18, 4051 Basel (CH). **DE ROSE, Francesco**; Im Erasmuhaus, Baumleingasse 18, 4051 Basel (CH). **FANI, Melpomeni**; Vizerektorat Forschung, Petersgraben 35, 4001 Basel (CH). **MILLUL, Jacopo**; Vizerektorat Forschung, Petersgraben 35, 4001 Basel (CH).

(74) Agent: **MORALES, Carl, A.** et al.; Goodwin Procter LLP, 100 Northern Avenue, Boston, MA 02210 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,

(54) Title: FIBROBLAST ACTIVATION PROTEIN-TARGETING RADIOPHARMACEUTICALS AND USES THEREOF



A B C

FIG. 1

(57) Abstract: The present disclosure relates to pharmaceutical compositions comprising a [^{61}Cu]Cu-labeled fibroblast activation protein (FAP) inhibitor-NODAGA conjugate. The present disclosure also relates to methods of imaging subjects suspected of having or diagnosed with a FAP-expressing cancer or tumor by administering the pharmaceutical compositions described herein and generating one or more radiographic images of the subject.

[Continued on next page]

WO 2026/010658 A2

LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*